Skip to main content
Erschienen in: Aesthetic Plastic Surgery 1/2017

23.12.2016 | Original Article

Long-Term Effects of the Collagenase of the Bacterium Clostridium histolyticum for the Treatment of Capsular Fibrosis After Silicone Implants

verfasst von: Sebastian Fischer, Yannick Diehm, Thomas Henzler, Martin R. Berger, Jonas Kolbenschlag, Anne Latz, Ericka M. Bueno, Christoph Hirche, Ulrich Kneser, Bohdan Pomahac

Erschienen in: Aesthetic Plastic Surgery | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Capsular contracture remains the most frequent long-term complication after augmentation mammoplasty with silicone implants. Thereby, the main part of the fibrotic capsule is collagen. The collagenase of the bacterium Clostridium histolyticum is approved for the treatment of fibrotic diseases and has been demonstrated to be effective for capsular fibrosis treatment in the short term. However, long-term effectiveness is currently unknown but mandatory for clinical utilization.

Materials and Methods

Forty-eight rats received miniature silicone implants and an injection with either collagenase (treatment group) or plain solvent solution (control group) 120 days post insertion. Ten and 60 days after the injections, the rats underwent 7-Tesla magnetic resonance imaging (MRI) and high-resolution ultrasound (HR-US). Capsule tissue was harvested, and capsule thickness and collagen density were evaluated through histology. Furthermore, the expression levels of inflammatory (CD68, IL4, IL10, IL12, IL13), pro-, and anti-fibrotic (TGFb1, TGFb3, Smad3, Col1-4) genes were analyzed using qRT-PCR.

Results

On days 10 and 60 after injection of collagenase, histology showed that capsule thickness was significantly reduced in the treatment group when compared with the control (p < 0.05). Thickness measurements were verified by MRI and HR-US analysis. Skin perforation occurred in two cases after collagenase injection. The initial up-regulation of pro-fibrotic and inflammatory genes 10 days after collagenase injection did not persist in the long term. Contrarily, on day 60, a slight trend towards lower expression levels with a significant down-regulation of TGFb3 was detected in the treatment group.

Conclusion

The collagenase of the bacterium C. histolyticum effectively degrades capsular fibrosis around silicone implants with stable outcomes throughout 60 days post injection. Skin perforation and adequate and uniform drug distribution within the implant pocket are issues that need to be addressed. Further studies are warranted to clarify whether collagenase injections have the potential to become a viable treatment option for capsular contracture.

No Level Assigned

This journal requires that authors 46 assign a level of evidence to each article. For a full 47 description of these Evidence-Based Medicine ratings, 48 please refer to the Table of Contents or the online 49 Instructions to Authors. www.​springer.​com/​00266.
Literatur
1.
Zurück zum Zitat American Society of Plastic Surgeons (2013) Complete plastic surgery statistics report American Society of Plastic Surgeons (2013) Complete plastic surgery statistics report
2.
Zurück zum Zitat Handel N, Cordray T, Gutierrez J, Jensen JA (2006) A long-term study of outcomes, complications, and patient satisfaction with breast implants. Plast Reconstr Surg 117:757–767 discussion 768–772 CrossRefPubMed Handel N, Cordray T, Gutierrez J, Jensen JA (2006) A long-term study of outcomes, complications, and patient satisfaction with breast implants. Plast Reconstr Surg 117:757–767 discussion 768–772 CrossRefPubMed
3.
Zurück zum Zitat Araco A, Caruso R, Araco F, Overton J, Gravante G (2009) Capsular contractures: a systematic review. Plast Reconstr Surg 124:1808–1819CrossRefPubMed Araco A, Caruso R, Araco F, Overton J, Gravante G (2009) Capsular contractures: a systematic review. Plast Reconstr Surg 124:1808–1819CrossRefPubMed
4.
Zurück zum Zitat Rosato RM, Dowden RV (1994) Radiation therapy as a cause of capsular contracture. Ann Plast Surg 32:342–345CrossRefPubMed Rosato RM, Dowden RV (1994) Radiation therapy as a cause of capsular contracture. Ann Plast Surg 32:342–345CrossRefPubMed
5.
Zurück zum Zitat Anderson JM, Rodriguez A, Chang DT (2008) Foreign body reaction to biomaterials. Semin Immunol 20:86–100CrossRefPubMed Anderson JM, Rodriguez A, Chang DT (2008) Foreign body reaction to biomaterials. Semin Immunol 20:86–100CrossRefPubMed
6.
Zurück zum Zitat Wilflingseder P, Hoinkes G, Mikuz G (1983) Tissue reactions from silicone implant in augmentation mammaplasties. Minerva Chir 38:877–880PubMed Wilflingseder P, Hoinkes G, Mikuz G (1983) Tissue reactions from silicone implant in augmentation mammaplasties. Minerva Chir 38:877–880PubMed
7.
Zurück zum Zitat Tamboto H, Vickery K, Deva AK (2010) Subclinical (biofilm) infection causes capsular contracture in a porcine model following augmentation mammaplasty. Plast Reconstr Surg 126:835–842CrossRefPubMed Tamboto H, Vickery K, Deva AK (2010) Subclinical (biofilm) infection causes capsular contracture in a porcine model following augmentation mammaplasty. Plast Reconstr Surg 126:835–842CrossRefPubMed
8.
Zurück zum Zitat Wick G, Backovic A, Rabensteiner E, Plank N, Schwentner C, Sgonc R (2010) The immunology of fibrosis: innate and adaptive responses. Trends Immunol 31:110–119CrossRefPubMedPubMedCentral Wick G, Backovic A, Rabensteiner E, Plank N, Schwentner C, Sgonc R (2010) The immunology of fibrosis: innate and adaptive responses. Trends Immunol 31:110–119CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Gurunluoglu R, Sacak B, Arton J (2013) Outcomes analysis of patients undergoing autoaugmentation after breast implant removal. Plast Reconstr Surg 132:304–315CrossRefPubMed Gurunluoglu R, Sacak B, Arton J (2013) Outcomes analysis of patients undergoing autoaugmentation after breast implant removal. Plast Reconstr Surg 132:304–315CrossRefPubMed
10.
Zurück zum Zitat Young VL (1998) Guidelines and indications for breast implant capsulectomy. Plast Reconstr Surg 102:884–891 discussion 892–884 CrossRefPubMed Young VL (1998) Guidelines and indications for breast implant capsulectomy. Plast Reconstr Surg 102:884–891 discussion 892–884 CrossRefPubMed
11.
Zurück zum Zitat Collis N, Sharpe DT (2000) Recurrence of subglandular breast implant capsular contracture: anterior versus total capsulectomy. Plast Reconstr Surg 106:792–797CrossRefPubMed Collis N, Sharpe DT (2000) Recurrence of subglandular breast implant capsular contracture: anterior versus total capsulectomy. Plast Reconstr Surg 106:792–797CrossRefPubMed
12.
Zurück zum Zitat Graf R, Ascenco AS, Freitas Rda S, Balbinot P, Peressutti C, Costa DF, Dos Santos Fde H, Ratti MA, Kulchetscki RM (2015) Prevention of capsular contracture using leukotriene antagonists. Plast Reconstr Surg 136:592e–596eCrossRefPubMed Graf R, Ascenco AS, Freitas Rda S, Balbinot P, Peressutti C, Costa DF, Dos Santos Fde H, Ratti MA, Kulchetscki RM (2015) Prevention of capsular contracture using leukotriene antagonists. Plast Reconstr Surg 136:592e–596eCrossRefPubMed
13.
Zurück zum Zitat Gilpin D, Coleman S, Hall S, Houston A, Karrasch J, Jones N (2010) Injectable collagenase Clostridium histolyticum: a new nonsurgical treatment for Dupuytren’s disease. J Hand Surg Am 35(2027–2038):e2021 Gilpin D, Coleman S, Hall S, Houston A, Karrasch J, Jones N (2010) Injectable collagenase Clostridium histolyticum: a new nonsurgical treatment for Dupuytren’s disease. J Hand Surg Am 35(2027–2038):e2021
14.
Zurück zum Zitat Hammoudeh ZS (2014) Collagenase Clostridium histolyticum injection for plantar fibromatosis (Ledderhose disease). Plast Reconstr Surg 134:497e–498eCrossRefPubMed Hammoudeh ZS (2014) Collagenase Clostridium histolyticum injection for plantar fibromatosis (Ledderhose disease). Plast Reconstr Surg 134:497e–498eCrossRefPubMed
15.
Zurück zum Zitat Hay DC, Louie DL, Earp BE, Kaplan FT, Akelman E, Blazar PE (2014) Surgical findings in the treatment of Dupuytren’s disease after initial treatment with clostridial collagenase (Xiaflex). J Hand Surg Eur 39:463–465CrossRef Hay DC, Louie DL, Earp BE, Kaplan FT, Akelman E, Blazar PE (2014) Surgical findings in the treatment of Dupuytren’s disease after initial treatment with clostridial collagenase (Xiaflex). J Hand Surg Eur 39:463–465CrossRef
16.
Zurück zum Zitat Freshwater MF (2012) What were the adverse events for Dupuytren’s patients treated with Xiaflex who had contractures less than 20 degrees? Hand 7:348–349CrossRefPubMedPubMedCentral Freshwater MF (2012) What were the adverse events for Dupuytren’s patients treated with Xiaflex who had contractures less than 20 degrees? Hand 7:348–349CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Levine LA, Cuzin B, Mark S, Gelbard MK, Jones NA, Liu G, Kaufman GJ, Tursi JP, Ralph DJ (2015) Clinical safety and effectiveness of collagenase Clostridium histolyticum injection in patients with Peyronie’s disease: a phase 3 open-label study. J Sex Med 12:248–258CrossRefPubMed Levine LA, Cuzin B, Mark S, Gelbard MK, Jones NA, Liu G, Kaufman GJ, Tursi JP, Ralph DJ (2015) Clinical safety and effectiveness of collagenase Clostridium histolyticum injection in patients with Peyronie’s disease: a phase 3 open-label study. J Sex Med 12:248–258CrossRefPubMed
18.
Zurück zum Zitat Holzer LA, Holzer G (2009) Injectable collagenase Clostridium histolyticum for Dupuytren’s contracture. N Engl J Med 361:2579–2580PubMed Holzer LA, Holzer G (2009) Injectable collagenase Clostridium histolyticum for Dupuytren’s contracture. N Engl J Med 361:2579–2580PubMed
19.
Zurück zum Zitat Fischer S, Hirsch T, Diehm Y, Kiefer J, Bueno EM, Kueckelhaus M, Kremer T, Hirche C, Kneser U, Pomahac B (2015) The collagenase of the bacterium Clostridium histolyticum for the treatment of capsular fibrosis after silicone implants. Plast Reconstr Surg 136:981–989CrossRefPubMed Fischer S, Hirsch T, Diehm Y, Kiefer J, Bueno EM, Kueckelhaus M, Kremer T, Hirche C, Kneser U, Pomahac B (2015) The collagenase of the bacterium Clostridium histolyticum for the treatment of capsular fibrosis after silicone implants. Plast Reconstr Surg 136:981–989CrossRefPubMed
20.
Zurück zum Zitat Fischer S, Hirche C, Reichenberger MA, Kiefer J, Diehm Y, Mukundan S, Alhefzi M, Bueno EM, Kneser U, Pomahac B (2015) Silicone implants with smooth surfaces induce thinner but denser fibrotic capsules compared to those with textured surfaces in a rodent model. PLoS ONE 10:e0132131CrossRefPubMedPubMedCentral Fischer S, Hirche C, Reichenberger MA, Kiefer J, Diehm Y, Mukundan S, Alhefzi M, Bueno EM, Kneser U, Pomahac B (2015) Silicone implants with smooth surfaces induce thinner but denser fibrotic capsules compared to those with textured surfaces in a rodent model. PLoS ONE 10:e0132131CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Syed F, Thomas AN, Singh S, Kolluru V, Emeigh Hart SG, Bayat A (2012) In vitro study of novel collagenase (XIAFLEX®) on Dupuytren’s disease fibroblasts displays unique drug related properties. PLoS ONE 7:e31430CrossRefPubMedPubMedCentral Syed F, Thomas AN, Singh S, Kolluru V, Emeigh Hart SG, Bayat A (2012) In vitro study of novel collagenase (XIAFLEX®) on Dupuytren’s disease fibroblasts displays unique drug related properties. PLoS ONE 7:e31430CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Brazzelli M, Cruickshank M, Tassie E, McNamee P, Robertson C, Elders A, Fraser C, Hernandez R, Lawrie D, Ramsay C (2015) Collagenase Clostridium histolyticum for the treatment of Dupuytren’s contracture: systematic review and economic evaluation. Health Technol Assess 19:1–202CrossRef Brazzelli M, Cruickshank M, Tassie E, McNamee P, Robertson C, Elders A, Fraser C, Hernandez R, Lawrie D, Ramsay C (2015) Collagenase Clostridium histolyticum for the treatment of Dupuytren’s contracture: systematic review and economic evaluation. Health Technol Assess 19:1–202CrossRef
23.
Zurück zum Zitat Sangkum P, Yafi FA, Kim H, Bouljihad M, Ranjan M, Datta A, Mandava SH, Sikka SC, Abdel-Mageed AB, Moparty K, Hellstrom WJG (2015) Collagenase Clostridium histolyticum (Xiaflex) for the treatment of urethral Stricture disease in a rat model of urethral fibrosis. Urology 86(647):e641 Sangkum P, Yafi FA, Kim H, Bouljihad M, Ranjan M, Datta A, Mandava SH, Sikka SC, Abdel-Mageed AB, Moparty K, Hellstrom WJG (2015) Collagenase Clostridium histolyticum (Xiaflex) for the treatment of urethral Stricture disease in a rat model of urethral fibrosis. Urology 86(647):e641
24.
Zurück zum Zitat Gelbard M, Lipshultz LI, Tursi J, Smith T, Kaufman G, Levine LA (2012) Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease. J Urol 187:2268–2274CrossRefPubMed Gelbard M, Lipshultz LI, Tursi J, Smith T, Kaufman G, Levine LA (2012) Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease. J Urol 187:2268–2274CrossRefPubMed
25.
Zurück zum Zitat Gelbard M, Goldstein I, Hellstrom WJG, McMahon CG, Smith T, Tursi J, Jones N, Kaufman GJ, Carson CC (2013) Clinical efficacy, safety and tolerability of collagenase Clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol 190:199–207CrossRefPubMed Gelbard M, Goldstein I, Hellstrom WJG, McMahon CG, Smith T, Tursi J, Jones N, Kaufman GJ, Carson CC (2013) Clinical efficacy, safety and tolerability of collagenase Clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol 190:199–207CrossRefPubMed
26.
Zurück zum Zitat Levine LA, Larsen SM (2015) Surgical correction of persistent Peyronie’s disease following collagenase Clostridium histolyticum treatment. J Sex Med 12:259–264CrossRefPubMed Levine LA, Larsen SM (2015) Surgical correction of persistent Peyronie’s disease following collagenase Clostridium histolyticum treatment. J Sex Med 12:259–264CrossRefPubMed
27.
Zurück zum Zitat Thomas A, Bayat A (2010) The emerging role of Clostridium histolyticum collagenase in the treatment of Dupuytren disease. Ther Clin Risk Manag 6:557–572CrossRefPubMedPubMedCentral Thomas A, Bayat A (2010) The emerging role of Clostridium histolyticum collagenase in the treatment of Dupuytren disease. Ther Clin Risk Manag 6:557–572CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Badalamente MA, Hurst LC, Hentz VR (2002) Collagen as a clinical target: nonoperative treatment of Dupuytren’s disease. J Hand Surg Am 27:788–798CrossRefPubMed Badalamente MA, Hurst LC, Hentz VR (2002) Collagen as a clinical target: nonoperative treatment of Dupuytren’s disease. J Hand Surg Am 27:788–798CrossRefPubMed
29.
Zurück zum Zitat Hurst LC, Badalamente MA, Hentz VR, Hotchkiss RN, Kaplan FTD, Meals RA, Smith TM, Rodzvilla J, Group CIS (2009) Injectable collagenase Clostridium histolyticum for Dupuytren’s contracture. N Engl J Med 361:968–979CrossRefPubMed Hurst LC, Badalamente MA, Hentz VR, Hotchkiss RN, Kaplan FTD, Meals RA, Smith TM, Rodzvilla J, Group CIS (2009) Injectable collagenase Clostridium histolyticum for Dupuytren’s contracture. N Engl J Med 361:968–979CrossRefPubMed
30.
Zurück zum Zitat Badalamente MA, Hurst LC (2007) Efficacy and safety of injectable mixed collagenase subtypes in the treatment of Dupuytren’s contracture. J Hand Surg Am 32:767–774CrossRefPubMed Badalamente MA, Hurst LC (2007) Efficacy and safety of injectable mixed collagenase subtypes in the treatment of Dupuytren’s contracture. J Hand Surg Am 32:767–774CrossRefPubMed
32.
Zurück zum Zitat Leask A, Abraham DJ (2004) TGF-beta signaling and the fibrotic response. FASEB J 18:816–827CrossRefPubMed Leask A, Abraham DJ (2004) TGF-beta signaling and the fibrotic response. FASEB J 18:816–827CrossRefPubMed
33.
Zurück zum Zitat Murata H, Zhou L, Ochoa S, Hasan A, Badiavas E, Falanga V (1997) TGF-beta3 stimulates and regulates collagen synthesis through TGF-beta1-dependent and independent mechanisms. J Invest Dermatol 108:258–262CrossRefPubMed Murata H, Zhou L, Ochoa S, Hasan A, Badiavas E, Falanga V (1997) TGF-beta3 stimulates and regulates collagen synthesis through TGF-beta1-dependent and independent mechanisms. J Invest Dermatol 108:258–262CrossRefPubMed
34.
Zurück zum Zitat Peimer CA, Wilbrand S, Gerber RA, Chapman D, Szczypa PP (2015) Safety and tolerability of collagenase Clostridium histolyticum and fasciectomy for Dupuytren’s contracture. J Hand Surg Eur 40:141–149CrossRef Peimer CA, Wilbrand S, Gerber RA, Chapman D, Szczypa PP (2015) Safety and tolerability of collagenase Clostridium histolyticum and fasciectomy for Dupuytren’s contracture. J Hand Surg Eur 40:141–149CrossRef
35.
Zurück zum Zitat Gelbard MK, Walsh R, Kaufman JJ (1982) Collagenase for Peyronie’s disease experimental studies. Urol Res 10:135–140CrossRefPubMed Gelbard MK, Walsh R, Kaufman JJ (1982) Collagenase for Peyronie’s disease experimental studies. Urol Res 10:135–140CrossRefPubMed
36.
Zurück zum Zitat Badalamente MA, Hurst LC (1996) Enzyme injection as a nonoperative treatment for Dupuytren’s disease. Drug Delivery 3:35–40CrossRef Badalamente MA, Hurst LC (1996) Enzyme injection as a nonoperative treatment for Dupuytren’s disease. Drug Delivery 3:35–40CrossRef
37.
Zurück zum Zitat Peak TC, Mitchell GC, Yafi FA, Hellstrom WJ (2015) Role of collagenase Clostridium histolyticum in Peyronie’s disease. Biologics 9:107–116PubMedPubMedCentral Peak TC, Mitchell GC, Yafi FA, Hellstrom WJ (2015) Role of collagenase Clostridium histolyticum in Peyronie’s disease. Biologics 9:107–116PubMedPubMedCentral
Metadaten
Titel
Long-Term Effects of the Collagenase of the Bacterium Clostridium histolyticum for the Treatment of Capsular Fibrosis After Silicone Implants
verfasst von
Sebastian Fischer
Yannick Diehm
Thomas Henzler
Martin R. Berger
Jonas Kolbenschlag
Anne Latz
Ericka M. Bueno
Christoph Hirche
Ulrich Kneser
Bohdan Pomahac
Publikationsdatum
23.12.2016
Verlag
Springer US
Erschienen in
Aesthetic Plastic Surgery / Ausgabe 1/2017
Print ISSN: 0364-216X
Elektronische ISSN: 1432-5241
DOI
https://doi.org/10.1007/s00266-016-0724-8

Weitere Artikel der Ausgabe 1/2017

Aesthetic Plastic Surgery 1/2017 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.